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                                                INTRODUCTION 
      Celiac disease is both a food intolerance and autoimmune disorder. Celiac disease is a 
kind of permanent intolerance to the storage protein “gluten” in  wheat, rye and barley.7 
      It is a chronic inflammatory state of predominantly the proximal small intestinal mucosa 
which resolves after gluten containing food are excluded from the diet and usually returns 
back when gluten is reintroduced.7 There are complex mechanisms of both adaptive and 
innate immune system involved, which result in atrophy of the small intestinal villi, 
deepening of the crypts, and infiltration of the lamina propria with intra-epithelial 
lymphocytes. 
      Idiopathic Non-Cirrhotic Intra-hepatic Portal Hypertension (NCIPH) defines one or more 
entities characterized by intra-hepatic portal hypertension and preserved liver function.18,19,20 
This definition encompasses a number of entities including Non-Cirrhotic Portal 
Fibrosis(NCPF), Idiopathic Portal Hypertension (IPH), Nodular Regenerative 
Hyperplasia(NRH), partial nodular transformation, incomplete septal cirrhosis, hepato-portal 
sclerosis and benign intra-hepatic portal hypertension and is sometimes difficult to 
differentiate from well-compensated cirrhosis. This excludes causes like extra-hepatic portal 
vein obstruction and Budd Chiari Syndrome.                                             
       The etio-pathogenesis of NCIPH is still poorly understood. A number of hypotheses have 
been proposed in the past. Arsenic toxicosis from contaminated drinking water has also been 
proposed as an etiological factor for NCIPH in India.20 Infective hypothesis has also been put 
forward with the possibility of umbilical sepsis, bacterial infection and diarrheal episodes in 
infancy and early childhood leading to portal pyemia, pylephlebitis resulting in thrombosis, 
sclerosis and obstruction of small and medium sized portal vein radicals.21  
7 
 
      A few reports have documented the association of celiac disease and idiopathic NCIPH.3 
The hypothesis of gut derived prothrombotic factors causing prothrombotic state was 
suggested of which IgA Anticardiolipin antibody was a potential candidate.3 
      In a retrospective analysis of prognostic indicators in 34 NCIPH patients, which was done 
to postulate that gut-derived prothrombotic factors may contribute to the pathogenesis of the 
disease in which  five of 31 (16%) patients tested, had celiac disease.1 
      We aimed to study the spectrum of celiac disease in patients with idiopathic non-cirrhotic 
intrahepatic portal hypertension (NCIPH)/cryptogenic chronic liver disease and to compare 
them with patients of chronic liver disease of known cause (Hepatitis B and Hepatitis C 
related).  
We also aimed to see the effects of gluten free diet in patients who have chronic liver disease. 
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                       AIMS AND OBJECTIVES  
       The hypothesis is that gut disorders predispose to NCIPH. Celiac disease is reported to 
be associated with NCIPH. In our centre, 50% of pts labelled as cryptogenic CLD are found 
to have NCIPH, after complete evaluation.2 
       Our aim was to study the spectrum of celiac disease in patients with idiopathic non-
cirrhotic intrahepatic portal hypertension (NCIPH)/cryptogenic chronic liver disease, and to 
see the effects of gluten free diet in patients with celiac disease and chronic liver disease. 
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                                              REVIEW OF LITERATURE 
NON-CIRRHOTIC INTRAHEPATIC PORTAL HYPERTENSION: 
 Historical Background: 
      During 1884 to 1910, Banti in Italy proposed the disorder morbus banti, which is 
characterized by primary cryptogenic splenomegaly and anemia not associated with any 
known hematologic disease.10 In 1954, Tisdale et al described four patients with portal 
hypertension and massive bleeding from esophageal varices in whom neither intra hepatic nor 
extra hepatic portal obstruction was found.22 
       Later Ramalingaswami et al in India (in 1962) noticed a similar disease while studying 
autopsy materials and characterized the histological lesion as obliterative portal venopathy.23 
In 1969, the title “non-cirrhotic portal fibrosis’ was officially adopted at a workshop 
organized by the Indian Council of Medical Research. Mikkelsen et al in Los Angeles 
described 35 patients with splenomegaly and non-cirrhotic portal hypertension, in whom 
phlebosclerotic processes were apparent in the intra and extra hepatic portal venous system 
and called the disease as “ hepato portal sclerosis.”24 
       With similar publications coming from various countries it is established that this entity 
(called with different names) does exist throughout the world, being more common in 
developing countries. The various names that are synonymously used are Hepatoportal 
sclerosis, NCPF, obliterative portal venopathy, Non-cirrhotic intra hepatic portal 
hypertension and idiopathic pre-sinusoidal portal hypertension. 
 
Epidemiology: 
        NCIPH has been reported to be common in socioeconomically disadvantaged people in 
India. The incidence of NCIPH has not been prospectively studied in India. Most of the 
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services from different parts of India show a male predominance of 2:1 to 4:1.12,15,16 In Japan, 
IPH was more common in older females with a female to male ratio of 3:1 and an average 
age of 40.6 years.23 
        In a study from North India it was reported that NCPF is on decline in India.25 But a 
recent study from our centre documented NCIPH as a common cause of cryptogenic 
intrahepatic portal hypertension.2  In a retrospective analysis from june 2005- june 2007, of 
517 patients who underwent liver biopsies at our centre, 227 had portal hypertension and 62 
of these patients had no documented cause of liver disease prior to biopsy. Causes identified 
after liver biopsy in these 62 patients were: idiopathic NCIPH (30 patients - 48%), cirrhosis 
(14), fatty liver disease (7) and other causes (11). 
 
 
Etiology: 
       Etiopathogenesis of NCIPH is poorly understood and a number of hypotheses have been 
proposed. 
 
Infective hypothesis: 
       Abdominal infection have been considered as a cause which can lead to portal pyemia 
and pylephlebitis, resulting in sclerosis, obstruction and thrombosis of small and medium 
sized portal vein radicals.26,27 
 
Experimental studies 
        Changes of NCIPH have been reported after injection of dead non-pathogenic colon 
bacilli into the portal vein of rabbits and dogs and after repeated injections of Escherichia 
coli.27 
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       In the same study, it was also noted that, of 34 patients of NCIPH 18 developed liver 
failure of which 13 either died or underwent liver transplantation, demonstrating that NCIPH 
is not a benign condition. Hepatic encephalopathy, older age at first presentation with 
NCIPH, portal vein thrombosis and celiac disease were predictors of reduced transplant-free 
survival.1 
 
Natural history of NCIPH: 
       The survival curve for patients with NCIPH is somewhat between that for those with 
cirrhosis and for a healthy population of comparable age.30 Good prognostic features in 
patients with NCIPH, a 2 and 5 year survival of nearly 100% after successful eradication of 
esophagogastric varices, have been described.31 
       Hillaire et al8 reported death in 4 out of 28 patients with NCIPH owing to terminal liver 
failure. Development of PVT in a patient with NCIPH may be a significant factor for poor 
prognosis, and ascites may indicate a deterioration of the condition in patients with NCIPH. 
Furthermore, PVT and ascites may be mutually related in this disease. 
 
Histopathology of NCPF/IPH 
 
Laboratory features: 
       Patients usually have preserved hepatic function. The tests of liver function are normal. 
Pancytopenia is found in the majority of patients. Anemia may be microcytic, hypochromic 
(due to GI blood loss) or normocytic, normochromic (due to hypersplenism).32 
Leucopenia(<4000/cumm) and thrombocytopenia (platelets <50,000/cumm) may also be 
present due to hypersplenism.  
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Imaging: 
        Ultrasonography shows a dilated and patent splenoportal axis with significantly 
thickened walls of the portal vein and the main branches. Doppler studies are helpful in 
identifying an occasional patient who has a thrombus in the intrahepatic branch of the portal 
vein.33 
 
Endoscopy: 
        Esophagogastric varices are seen in 85-95% of patients who have NCIPH. Furthermore, 
patients with NCIPH have large varices more often (90%) compared with cirrhotic patients 
(79%). 
 
 
Hemodynamics in NCPF/IPH: 
       The portal vein pressures are elevated markedly in patients who have NCIPH. Two 
pathoanatomic sites of obstruction have been identified. A pressure gradient exists between 
the spleen and the liver (intrasplenic pressure – intrahepatic pressure [IHP]) and another 
exists between the IHP and the wedge hepatic venous pressure (WHVP) [IHP – WHVP]. 
        Generally, the WHVP is normal or only slightly elevated in NCPF. Variceal pressure 
also has been studied in these patients and is comparable to that in cirrhotic portal 
hypertension.34 Intravariceal pressure measurement is considered as the indicator of portal 
pressures in these patients. 
 
HISTOPATHOLOGICAL FEATURES OF NCIPH 
Autopsy liver- Gross examination may reveal a normal, enlarged, or even shrunken liver. 
Subcapsular septation is seen with normal architecture of deep parenchyma. Sclerosis of large 
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to small intrahepatic portal vein branches and approximation of portal tracts to surface has 
been documented.78,79,80 Histological features noted in autopsies include increased portal 
collagenous connective tissue and sclerosis and obliteration of small branches of portal veins 
in most cases.32 This histological hallmark of NCPF was termed obliterative portal venopathy 
by Nayak and Ramalingaswami. Intimal fibrosis and elastosis can also occur, leading to 
subendothelial thickening of the walls of large- and medium-sized portal vein branches 
causing luminal compromise. Veins may be thickened to the extent that they resemble an 
artery. Mild inflammation is seen in a few cases. 
 
Needle biopsies-Biopsy material may show only mild and subtle changes from normal. These 
changes include obliterated and fibrosed portal tracts and obliterated veins, or fibrous 
expansion of portal tracts.32 Alternatively there may be dilatation of vessels in or near portal 
tracts, with vessel-like dilatation of sinusoids. Ludwig et al studied the changes in 25 liver 
biopsies. Changes in the portal tract included capillary dilatation, phlebosclerosis, and 
fibroelastosis of the stroma. Portal vein dilatation is also seen.78,79,80 
 
Wedge biopsies- Wedge biopsies show changes similar to autopsy material, but changes in 
medium and large portal vein branches may not be seen if not sampled adequately.32 A deep-
core wedge biopsy (not broad-based wedge) along with a needle biopsy should be taken, as 
they would complement each other. 
16 
 
 
                                 
  
CELIAC DISEASE: 
 
        It is characterized by a chronic inflammation of the proximal small intestinal mucosa 
that improves when foods containing gluten are excluded from the diet and returns when 
these foods are reintroduced. There are complex adaptive and innate immune reactions which 
result in chronic inflammation. There is diffuse atrophy of the small intestinal villi, (varying 
from mild to complete atrophy) deepening of the crypts and infiltration of the lamina propria 
and intraepithelial compartments with chronic inflammatory cells.   
 
Pathology:  
       There are varying degrees of inflammation and histological changes that occur in patients 
with celiac disease on a gluten containing diet. A progression in the mucosal injury was 
Figure 4: Long core showing fibrotic septa     
without cirrhosis 
Figure 5: Fibrosis around the portal tract 
with a hypoplastic venule 
           Figure 6: Angiomatosis 
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described by Marsh et al which has evolved into a grading of histologic damage that reflects 
the varying degrees of villous atrophy and inflammatory changes seen in duodenal biopsies 
of these patients. The presence of increased intraepithelial lymphocytes only (Marsh grade 1), 
is not specific for celiac disease.35,36 Many of these patients are asymptomatic but some of 
these patients may have diarrhea that resolves with a gluten-free diet.37  
 
Pathogenesis: 
 
Gluten 
        Celiac disease is an autoimmune disease secondary to dietary ingestion of gluten. Gluten 
encompasses the proteins derived from wheat, barley and rye. These proteins contain 
glutamines and prolines that undergo only partial  digestion in the upper gastrointestinal tract, 
resulting in  peptide derivatives. It is a 33–amino acid peptide sequence from a gliadin that 
survives digestion and contains several motifs that are especially immunogenic to the celiac 
intestine.38 It is the persistence of highly immunogenic peptides and their passage through the 
epithelial barrier which reach antigen-presenting cell in the lamina propria of the intestine. 
Mucosal Immune Response  
        Both innate and adaptive immune responses are seen. The adaptive response is mediated 
by gluten-reactive CD4_ T cells in the lamina propria that recognize certain gluten derived 
peptides when they are presented by the HLA class II molecules DQ2 or DQ8. These cells 
then produce proinflammatory cytokines. Glutamine residues in the gluten peptides undergo 
deamidation with the formation of a negatively charged glutamic acid residue, the resulting 
peptide can bind in the binding groove of the DQ2 or DQ8 molecules with a higher affinity. 
Tissue transglutaminase (tTG) in the intestine performs  targeted deamidation. T cells which 
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are activated by gluten henceforth produce interferon gamma and other proinflammatory 
cytokines causing inflammatory response and damage the intestinal mucosa. 
 
SPECTRUM OF CELIAC DISEASE : 
Table 1: Clinico-pathologic spectrum of Celiac Disease7 
Type Spectrum 
 
Classic 
It is the most commonly described form. These are the patients with classic 
features of intestinal malabsorption and have fully developed gluten-induced 
villous atrophy and other classic histologic features. They present because of GI 
symptoms. 
 
Atypical 
It appears to be the most common form. They generally have little or no GI 
symptoms but come because of other reasons such as iron deficiency, 
osteoporosis, short stature or infertility. They have fully developed villous 
atrophy. Because these are ‘asymptomatic’ from the GI perspective, majority go 
undiagnosed. 
 
Silent 
It refers to asymptomatic patients who are discovered to have gluten induced 
villous atrophy. They are found after serologic screening or perhaps during 
endoscopy and biopsy for other reasons. They are clinically silent because in 
that they do not manifest any clear GI symptoms or associated atypical features 
of celiac disease such as iron deficiency or osteoporosis. 
 
Latent 
It represents patients with a previous diagnosis of celiac disease that responded 
to GFD and who retain a normal mucosal histology or manifest only an increase 
in intra-epithelial lymphocytes. It can also represent patients with currently 
normal mucosa on a gluten-containing diet who will subsequently develop 
celiac disease. 
    
      Figure 4: The Celiac Disease iceberg model 
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Diagnosis: 
ESPGHAN CRITERIA: 
 Biopsy    Biopsy Biopsy 
       
Gluten -----    ------- 
Symptoms & 
screening tests 
+++ +/- - - ++ 
Intestinal mucosa Flat  N N Flat 
Time (months)      ----0----------------------------------------------------------------------------------12---------15---
Phase 1 2 3 
 
 
REVISED ESPGHAN CRITERIA: 
 
 
 
 
 
SEROLOGY : 
        The various serologic tests used for detecting celiac disease include antigliadin 
antibodies (AGA), EMA and Anti-tTG antibodies (tTGA).  
 
EMA. EMA is measured using an immunofluorescence technique with monkey esophagus or 
human umbilical cord as the tissue substrate. The pooled sensitivity of the test is 97.4% (95% 
confidence interval [CI]- 95.7–98.5), and the pooled specificity is 99.6% (95% CI, 98.8 –
99.9) using monkey esophagus as substrate.38,39  
        The specificity of the IgA EMA using human umbilical cord (HU) as substrate in adults 
has been reported as 100% in nearly all the studies with sensitivity, ranging from 87% to 
Figure 5: Celiac Disease diagnostic protocol proposed by ESPGHAN in 1970. 
1. History and clinical presentation compatible with CD 
• Serologic screening compatible with CD 
• Histologic findings compatible with CD 
• Obvious clinical and serologic response to GFD 
• Subject > 2 years old 
• Rule out other clinical conditions mimicking CD
Definitive diagnosis of CD 
Figure 6: Revised criteria for the diagnosis of Celiac Disease. 
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100%. The pooled sensitivity and specificity of this test were 90.2% (95% CI, 86.3–92.5) and 
99.6% (95% CI, 98.4 –99.9), respectively. 
 
tTGA. tTGA is measured by quantitative enzyme linked immunosorbent assay (ELISA) with 
guinea pig liver (GP) or human recombinant or red cell–derived tTG as the substrate. 
IgA tTGA-GP. Studies have revealed variable results with the overall sensitivity  close to 
90%38 and specificity was 95.3% (95% CI, 92.5%– 98.1%) 
.IgA tTGA-HU. Most commercial tests use human recombinant or red blood cell– derived 
tTG as substrate. The pooled sensitivity and specificity of IgA tTGA-HU were 95.1% (95% 
CI, 91.8%–98.1%) and 98.3% (95% CI, 97.1%–99.6%), respectively in adults. There does 
not appear to be a major difference between tests that use recombinant tTG and those that use 
tTG derived from red blood cells.38 Overall, the specificity of IgA tTGA is greater than 95% 
with  a sensitivity in the range of 90%–96%. False-positive results of the IgA tTG-HU (e.g., 
in patients with liver disease, congestive heart failure, arthritis and inflammatory bowel 
disease) are less commonly seen now. 
 
IgA AGA. The bulk of the data suggest that the specificity of the IgA AGA approximates 
90%. 
 
Disadvantages of the Serological Diagnosis of Celiac Disease in Patients with Chronic 
Liver Disorders. 
        The accuracy of serological tests which are used commonly for the diagnosis of celiac 
disease is decreased in patients with chronic liver disease.13  The interpretation of the results 
has to be done carefully in these patients. 
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Anti-Tissue Transglutaminase Antibody and Endomysial Antibodies: 
       With the first-generation tTGA tests which used tTG derived from guinea, pig there were 
many false positives in patients with chronic liver diseases. This was due to the antigens 
present in the crude extract of pig liver and probably secondary to immune dysregulation 
(hypergammaglobulinemia) associated with the underlying disease per se. The specificity and 
number of false positives could be reduced by use of human tTG sequences.13,14,65 However, 
false positives are rare with these assays but can be seen, in patients with advanced chronic 
liver disease due to the formation of antibodies directed against tTG in the diseased 
liver.13,14,65 The endomysial antibody indirect immunofluorescence assay has a very high 
specificity and is a  useful test for patients with chronic liver disease.  
HISTOLOGY: 
        A small intestinal mucosal biopsy is currently considered as the gold standard for the 
diagnosis of celiac disease.38,41 The changes in the small intestinal mucosa are usually graded 
as per the Marsh grading from 0-IV as described below. 41,42  
 
Table 2: Marsh grading mucosal biopsy in Celiac Disease7
Grade Histologic feature 
Marsh 0 Normal villous and mucosal architecture 
 
Marsh I 
Infiltrative 
   Normal villous and mucosal architecture 
   Increased numbers of intraepithelial lymphocytes
Marsh II Hyperplastic 
    Enlarged crypts and with increased crypt cell division  
 
 
 
 
 
Marsh III 
a. Partial villous atrophy 
Shortened blunt villi 
Mild lymphocyte infiltration 
Enlarged hyperplastic crypts 
b.  Subtotal villous atrophy 
Clearly atrophic villi, but still rcognizable 
Enlarged crypts 
c. Total villous atrophy 
Complete loss of villi 
Severe crypt hyperplasia, and infiltrative inflammatory lesion 
 
Marsh IV 
Hypoplastic  
    Total villous atrophy 
    Normal crypt depth, but hypoplasia 
    Normal intraepithelial lymphocyte count 
22 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       Mucosal changes can be patchy and hence it is important to take multiple endoscopic 
biopsy specimens from the proximal small intestine. Many other diseases resemble celiac 
disease histologically need consideration before a diagnosis of celiac is made. 
 
 
Treatment: 
 
        The treatment of the disease is a gluten-free diet viz. wheat, barley and rye, which could 
be advised with the help of an experienced dietician. Improvement is noted within few weeks 
after gluten exclusion. On follow up on GFD after 6 months to 1 year the serologic tests 
results usually normalize with symptomatic improvement also. Repeat histology is not 
required in those who have a response to GFD. 
 
 
 
 
 
 
Figure 7: Spectrum of malabsorption and symptoms in celiac disease. The magnitude 
of malabsorption and symptoms often correlates with extent of mucosal injury. 
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Follow up on a Gluten Free Diet(GFD): 
 
       Patients should be regularly assessed on GFD by history regarding patient’s compliance 
with the diet and to reinforce for the same by an expert team involving the dietician and 
clinician. Symptomatic improvement on GFD may not give an accurate assessment of 
compliance. Repeat serologic testing with monitoring for titres after 6 months or more on a 
GFD can help in assessing any histologic improvement and compliance with a GFD. It has 
been seen that the sensitivity of the serologic tests decreases with lower Marsh grades i.e. 
Marsh grades I and II and serologic tests usually become negative and the titres usually 
decrease as the findings on histology improve but may not revert to normal.42-45 Monitoring 
serologies (i.e., tTGA or EMA) can distinguish between those who are complaint with the 
noncompliers with diet.46-51 In adults the improvement is usually slow as compared to 
children, which can take more than 2 years and frequently also is incomplete which cannot be 
explained only with dietary non-compliance.52-55 In adults, negative serologic test results do 
not necessarily reflect improvement in histology.44 
 
 
 
MILD ENTEROPATHY:  
 
       In a study by Kurppa et al there was a suggestion that mucosal damage develops 
gradually and patients may experience clinical symptoms before histologic changes appear. 
They studied 70 consecutive adults with positive EMA, and of these, 23 had only mild 
enteropathy (Marsh I–II) and they were randomized either to continue on a gluten-containing 
diet or start GFD. Forty seven patients (disease controls) had mucosal lesions on duodenal 
histology compatible with celiac disease (Marsh III). It was further noted that in the gluten-
containing diet group (Marsh I–II) the small-bowel mucosal deterioration was seen in all 
patients, and the symptoms and abnormal antibody titres persisted. In the GFD group (Marsh 
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I–II) the symptoms were alleviated, antibody titres decreased and mucosal inflammation 
diminished equally to celiac controls (Marsh III).6 
        In a recent study by Adrian Cummins et al the authors described morphometric changes 
in duodenal biopsies in untreated and treated subjects with celiac disease with follow-up of 4 
years.71 They looked at the relationship of changes in morphometry to histologic assessment 
using Marsh criteria, self-reported compliance to a GFD, and changes in celiac serology. The 
described morphometric changes in duodenal biopsies in untreated and treated subjects with 
celiac disease  after 6, 24, and 48 months of a GFD were 26.3, 52.4, and 63.1, respectively. 
Further the relationship of Marsh grades to intestinal morphometry was assessed in a subset 
of subjects who had both Marsh grades and duodenal morphometry. Patients with Marsh 
grades 0, 1, and 2 showed a reduction in villous area as compared to controls .71 
 
 
INTESTINAL PERMEABILITY: 
 
        Patients with celiac disease have an increased gut permeability.11 It has been 
hypothesized that this in genetically predisposed individuals cause an immune response 
against antigens sharing common epitopes to self liver proteins or cryptic antigens unmasked 
by dietary gliadin. The mucosal damage which occurs in patients with CD leads to exposure 
of tissue transglutaminase enzyme, the target antigen in these patients which is recognized by 
anti-endomysial antibody. The hypothesis has been shown by a study showing deposition of 
IgA TTG antibody in liver biopsy of two patients with active celiac disease.10 
        The permeability can be tested by using lactulose mannitol test. Both are water soluble 
molecules of which mannitol is easily absorbed while lactulose (larger molecule) is only 
slightly absorbed. Patients would be asked to drink a solution containing both mannitol and 
lactulose in fasting state. Urine would be collected for six hours and the amount present in 
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urine would reflect how much was absorbed by the body. In normal healthy people the test 
shows high levels of mannitol and low levels of lactulose. In celiac disease there is a 
reduction in the fractional excretion of mannitol and an increase in that of lactulose with an 
increase in the lactulose:mannitol ratio which reverses in majority of patients on a gluten free 
diet.59 Increase in permeability is a sensitive test for the presence of gluten in the diet.59 
Evidence comes from animal studies which have shown that abnormal permeability precedes 
disease. 
        In humans there is paucity of data for altered gut permeability prior to the onset of 
disease.56,57 In some studies it has been seen that gluten removal does not totally resolve the 
underlying defect, reflecting some of the damage is irreversible and an existing alteration in 
the tight junctions.57 In one study about one third of first degree relatives had abnormal 
permeability.58 Approximately 8% of these had a positive endomysial antibody test, 
underwent biopsy and were demonstrated to have asymptomatic celiac disease but the reason 
for the abnormal permeability in the remainder was not reported. 
 
 
 
LIVER IN CELIAC DISEASE : 
 
The prevalence of celiac disease has been seen in patients of cryptogenic hyper-
transaminemia (1.5-9%), autoimmune hepatitis (2.9-6.4%), Primary Biliary Cirrhosis-PBC 
(0-6%) and Primary Sclerosing Chlorangitis-PSC (1.5%). It has also been associated with 
Non-Alcoholic Fatty Liver Disease-NAFLD (~3.4%).6 
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CELIAC DISEASE AND CRYPTOGENIC CHRONIC LIVER DISEASE 
/NON-CIRRHOTIC INTRAHEPATIC PORTAL HYPERTENSION: 
 
        A retrospective analysis of prognostic indicators in 34 NCIPH patients was done to 
postulate that gut-derived prothrombotic factors may contribute to the pathogenesis and 
prognosis of NCIPH. A search for associated gut diseases was also done in which five of 31 
(16%) tested had celiac disease.1  
        Prevalence of elevated initial serum IgA anticardiolipin antibody (CLPA) was 
significantly higher in NCIPH (36% of patients tested), compared to Budd–Chiari syndrome 
(6%) and celiac disease without concomitant liver disease.1 An association of elevated serum 
cardiolipin antibodies, non-cirrhotic intrahepatic portal hypertension and celiac disease had 
been suggested by Austin et al.3 The hypothesis of gut derived prothrombotic factors causing 
prothrombotic state was suggested, of which IgA-anticardiolipin was a potential candidate.3 
Cancado et al (J. of clin gastroenterol, Feb 2006) showed association of hepatopulmonary 
syndrome and IgA cardiolipin.4 A case was reported by M’saddek, who showed celiac 
disease in a patient of idiopathic portal hypertension (Gastroenterol Clin Biol, Oct 2007) and 
positive antibodies in 5 patients of celiac disease and nodular regenerative hyperplasia. 
Table 3: Liver diseases associated with Celiac Disease81
Isolated hypertransaminemia with parenchymal damage reversible on GFD(celiac hepatitis) 
Cryptogenic cirrhosis 
Autoimmune liver disorders 
   Primary biliary cirrhosis 
   Autoimmune hepatitis: type 1 and type 2 
   Autoimmune cholangitis 
   Primary sclerosing cholangitis 
Chronic hepatitis C infection/antiviral therapy 
Hemochromatosis 
Non-alcoholic fatty liver disease(NAFLD) 
Acute liver failure 
Regenerative nodular hyperplasia 
Hepatocellular carcinoma  
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       Other case reports of association of celiac with NCPIH from India have been published 
by B C Sharma et al who reported 2 cases of celiac disease associated with NCPF.63  
       In another study of 327 consecutive patients with chronic liver disease for Gliadin 
antibodies (IgA and IgG). They were detected in 19 patients (6%), a prevalence six times 
greater than that found in healthy blood donors. In 9 of the 19 patients the etiology of the 
liver disease was considered as cryptogenic. The occurrence of Gliadin antibody was noted to 
be independent of the degree of hepatocellular impairment. Small bowel biopsy was done in 
5 of the 10 patients in whom the diagnosis of celiac disease was confirmed. The authors 
suggested that the prevalence of CD in patients with chronic liver disease to be at least 1.5%, 
that is, 15 times higher than in the general population. They also suggested that the possible 
presence of CD should be considered in cases of chronic ‘cryptogenic’ liver disease.60 
 
Effect of gluten free diet on liver disease: 
 
      The effect of a GFD on halting progression of liver disease associated with CD is 
presently not clear. A response to gluten free diet with an improvement in clinical 
manifestations and laboratory abnormalities has been described in  both adults and children 
with advanced liver disease.62,63 The general condition, jaundice, ascites, bilirubin, ALT, 
albumin, and INR improved after 6 months of strict adherence to a GFD in the patients with 
advanced liver disease and CD. Whether severe histological changes in the liver of patients 
with CD are reversible is still controversial, but the regression and even reversal of severe 
fibrosis in a liver biopsy after gluten exclusion has been reported.62,64 
        In another study done in Finland,8 185 adults who underwent liver transplantation, a 
dramatic improvement was seen on a gluten free diet (given in 4 untreated patients) and 3 
patients were subsequently delisted from the transplant list. A similar case was reported by 
Ojetti et al.9 
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        In a study by Lindgren et al, of the 5 patients diagnosed with celiac disease had a 
complete normalisation of liver functions on a gluten free diet.60 
 
Celiac disease in India : 
 
        The overall seroprevalence of celiac disease was 1.44% and the overall prevalence of 
celiac disease was 1.04% in a recent study from north India.67 In another study by Sood et al, 
amongst school children the prevalence of celiac disease was reported as 0.3 to 1% in 310.66 
         In another study by Lal et al the seroprevalence amongst school children in northern 
india was reported. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
29 
 
                                         METHODOLOGY 
AIM 1:  To Study the spectrum of celiac disease in patients of cryptogenic chronic liver 
disease.  
        This was a case-control study  in  which  the spectrum of celiac disease was studied in 
cases i.e. consecutive patients of cryptogenic chronic liver disease or non–cirrhotic 
intrahepatic portal hypertension and in control group which  included patients of chronic liver 
disease of known etiology i.e. hepatitis B or C related. The period of recruitment was over a 
period of 2 years (Jan, 2009 to Jan, 2011). The study was approved by Research and Ethics 
committee (IRB-Institutional Review Board) of the Christian Medical College, Vellore. 
Patients who did not provide consent or had hepatocellular carcinoma and Budd-chiari 
syndrome were excluded. 
Diagnosis of Celiac disease: In all enrolled patients the evaluation of disease included : 
1. Symptoms: i.e. diarrhea, bloating, flatulence, steatorrhea etc using symptom 
score as per Kurppa et al6 
                         0:  none 
    1: slight(occasionally 1 or more of: abdominal pain, diarrhea,                        
tiredness or joint pain) 
    2:   moderate (more persistent, disturbing normal life) 
    3:  severe (severe daily symptoms significant restricting normal life or 
excess weight loss).  
Serology: IgA–TTG antibody with titres at the time of diagnosis. The evaluation of IgA 
antibody against neo-epitopes of tissue transglutaminase (tTG) in human serum was 
performed using the commercially available solid-phase enzyme immunoassay kit (ELISA) 
(AESKULISA Celichek, Germany and AIDA, Germany). The assay employed recombinant 
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human transglutaminase. Serum samples diluted to 1:101 were incubated in the microplates 
coated with human recombinant tissue transglutaminase. Patient’s antibodies, if present in the 
specimen, would bind to the antigen. Subsequently the unbound fraction was washed off. 
Afterwards, anti-human immunoglobulins conjugated to horse radish peroxidase (conjugate) 
was incubated in the microplates and reacted with the antigen–antibody complex of the 
samples. Unbound conjugate was washed off. Addition of TMB-substrate generated an 
enzymatic colorimetric (blue) reaction, which was stopped by diluted acid (color change to 
yellow). The rate of color formation from the chromogen is a function of the amount of 
conjugate bound to the antigen–antibody complex and is proportional to the initial 
concentration of the respective antibodies in the patient sample. The absorbance of resulting 
product at 450 nm was read within 30 min to determine the optical density (OD). A standard 
curve was obtained by plotting the OD of each calibrator (y axis) against corresponding 
concentrations in U/ml(x-axis). From this standard curve, quantitative interpretation of 
patient’s sample in U/ml was obtained for their respective optical densities. The test would be 
interpreted as titres<15 U/ml as negative, 15-20 U/ml as borderline positive and >20 U/ml as 
positive. 
 
Anti-cardiolipin antibodies (IgG, IgM and IgA ) : Similarly anti-cardiolipin antibodies were 
detected using the ELISA (Varelisa kit) 
Varelisa Cardiolipin (IgM, IgG and IgA) antibodies is an indirect noncompetitive enzyme 
immunoassay for the semiquantitative and qualitative determination of cardiolipin antibodies 
in human serum or plasma. The wells of a microplate are coated with bovine cardiolipin 
antigen. Antibodies (IgM, IgG and IgA ) specific for cardiolipin present in the patient sample 
bind to the antigen. In a second step the enzyme labeled second antibody (conjugate) binds to 
the antigen-antibody complex which leads to the formation of an enzyme labeled conjugate-
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antibody-antigen complex. The enzyme labeled antigen-antibody complex converts the added 
substrate to form a colored solution. The rate of color formation from the chromogen is a 
function of the amount of conjugate complexed with the bound antibody and thus is 
proportional to the initial concentration of the respective antibodies in the patient sample. A 
standard curve was obtained by plotting the OD of each calibrator (y axis) against 
corresponding concentrations in U/ml(x-axis). From this standard curve, quantitative 
interpretation of patient’s sample in U/ml was obtained for their respective optical densities. 
The test would be interpreted as titres<10 U/ml as negative, 10-15 U/ml as equivocal and >15 
U/ml as positive. 
 
 
Duodenal biopsy: The biopsy grading was done according to the Marsh criteria as described 
above. 
 
Spectrum of disease: It was assessed as follows based on biopsy and serology. 
 
 
 
 
 
Gut permeability: Celiac disease also causes a “leaky gut” with increase in   intestinal 
permeability. The standard test for leaky gut syndrome is the mannitol and lactulose test by 
HPLC technique. Both are water soluble molecules that the body can't use. Mannitol is easily 
absorbed by people with healthy intestinal linings. Lactulose is a larger molecule and is only 
Table 4: Spectrum of disease based on biopsy and serology 
Duodenal biopsy 
(Marsh grade) 
IgA-TTG antibody Spectrum 
 
III/IV + Celiac disease 
I/II + Celiac enteropathy 
0 + Latent celiac disease 
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slightly absorbed. Patients would be asked to drink a solution containing both mannitol and 
lactulose in fasting state. Urine would be collected for six hours and the amount present in 
urine would reflect how much was absorbed by the body. A healthy test shows high levels of 
mannitol and low levels of lactulose. If high levels of both molecules are found, it indicates a 
leaky gut condition. If low levels of both molecules are found, it indicates general 
malabsorption of all nutrients.The test would be interpreted as a ratio greater than 0.072 as 
positive and indicative of increased permeability83 
Other tests: For all cases at diagnosis in  
CBC  
Serum Ferritin/iron studies 
Serum Vit. B12 /folate 
A/G ratio 
      This was followed by subjecting these patients on a gluten free diet which would be done 
by the principal investigator. The patient was asked to avoid wheat made products and all 
packed items containing “gluten” as ingredient to be avoided. 
 
Evaluation for Chronic liver disease:  
       Etiological work up of chronic liver disease [Liver profile (AMA, SLA, LKM, SMA), 
ANA], Wilsons (serum ceruloplasmin), 24-hr urine copper, viral serology, Iron studies. 
 
CTP Score  
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Liver biopsy with measurement of HVPG where clinically indicated for diagnosis. Patients 
having a normal HVPG and no evidence of cirrhosis in liver biopsy were considered as non-
cirrhotic intrahepatic portal hypertension. 
USG Abdomen with colour Doppler  
Serum AFP 
Gastroscopy: For assessment of varices  
AIM 2: To see the effects of gluten-free diet in patients with chronic liver disease. This was a 
before and after intervention study in which we looked at the effects of gluten-free diet on all 
patients diagnosed with celiac disease. 
 Assessment of liver functions at baseline and after a minimum of 3  months of gluten 
free diet 
          Liver functions   
CTP score 
Complications  
Ascites 
Hepatic encephalopathy 
Variceal bleed  
Spontaneous bacterial peritonitis  
          Intestinal functions: At baseline and follow up 
              Clinical symptoms graded using scoring as per Kurppa et al. 
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                        Compliance with gluten free diet70  
                        Body Weight 
                        Hemoglobin 
                        Serum Albumin 
                        Intestinal permeability test using lactulose-mannitol test 
                        Titres of Anti-TTG antibody on follow up 
                         Repeat gastroscopy with duodenal biopsy where possible. 
      The diet was explained by the principal investigator verbally to the patient and was 
monitored by a detail history on follow up. The patients were asked to avoid all wheat and 
wheat based products and all packed items containing gluten as ingredient. Compliance to 
gluten-free diet was defined as follows: (3) = more than one serve of gluten-containing 
food/week; (2) = up to one serve of gluten-containing food/week; (1) = one serve of gluten in 
a month; (0) no gluten-containing food/week.70 
Consent: written informed consent was taken from all enrolled patients for the study. 
 
STATISTICAL ANALYASIS : 
Sample size:  
  
Based on the objective to study the association between celiac disease (CD) and 
cryptogenic chronic liver disease, the study design has been Case Control Study. As 
the prevalence has been reported to be 30% in the,5 cryptogenic chronic liver disease 
while this has been ~5% in the control group(HBV and HCV related chronic liver 
disease)15 and keeping Alpha and Beta errors at 5% and 20%, and expecting 6 times 
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more association in the group, the cryptogenic chronic liver disease sample size 
needed is 50 cases and 100 controls. However, looking at recent data and due to 
financial constraints the sample size was calculated to be kept as 50 cases and 
controls. 
  
 Statistical Methods: 
  
In order to study the association, bivariate analyses were done and the associations 
were studied using chi-square test (Fisher exact test). A p value of less than or equal 
to 0.05 was considered statistically significant. 
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                                                   RESULTS  
Age and sex distribution: 
      The mean age of the cases was 43 years and in controls it was 45 years. 77% of the cases 
and 89% of the controls were males.  
Table 5: Age and sex distribution 
 CASES 
Cryptogenic CLD 
(n=60) 
CONTROLS 
HBV/HCV related CLD 
(n=59) 
p value 
Age(yrs)mean(SD) 43 (10) 45(11) 0.27 
Sex (M:F) 46:14 53:6 0.08 
                                                                                                                                                
Geographic distribution: 
        The majority of patients in cases and controls were from Eastern India. 45 (75%) cases 
and 46 (78%) controls were from eastern India, 9 (15%) cases and 12 (20%) controls from 
southern India, 5 (8%) of cases and 0 (0%) controls from northern India, 1 (2%) cases and 1 
(2%) control was from western India. 
  
 
 
Figure 8: Geographic distribution of cases and controls. 
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Baseline parameters:  
 
Table 6: Baseline clinical parameters in cases and controls 
 CASES 
 Cryptogenic CLD  
(n=60) 
CONTROLS 
Hep B/C related CLD 
(n=59) 
p value 
Past/present 
Jaundice 
14 11 0.66 
Ascites 25 30 0.26 
Encephalopathy 9 6 0.58 
Variceal bleed 18 19 0.69 
CTP (A:B:C) 41:12:7 28:20:11  
CTP score-
mean(SD) 
6(1.9) 7(2.3) 0.01 
 
 
 
Table 7: Baseline clinical parameters in cases and controls 
 CASES 
 Cryptogenic CLD  
(n=60) 
CONTROLS 
Hep B/C related CLD 
(n=59) 
p value 
Bilirubin (gm/dl) 1.9(4) 2(2.7) 0.89 
Protein (gm/dl) 7.5(0.8) 7.6 (0.9) 0.53 
Albumin(gm/dl) 3.5 (0.9) 3.2 (0.8) 0.06 
Prothrombin time 15 (4.3) 16 (4.4) 0.40 
INR 1.2(0.4) 1.3(0.4) 0.10 
Creatinine 0.9(0.2) 1.2(0.9) 0.02 
Haemoglobin(gm%) 11 (2) 11 (2) 0.74 
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Evaluation for celiac disease in cases and controls: 
IgA-TTG Antibody: In the cases IgA-TTG antibody was positive in 40/58  (69%) of cases 
however it was positive in 16/59 (27%) controls (p=0.00).  
 
 
 
Duodenal biopsies: 
       Duodenal biopsies were done in 51 cases and 28 controls. Marsh 0 (normal) were seen in 
19/51(37%) cases and 19/28 (68%) of controls. Marsh I seen in 19/51(37%) cases and 8/28 
(29%) controls. Marsh II seen in 1/51 in cases and 1/28 of controls. Marsh III changes on 
duodenal biopsies were seen in 12/51 (24%) of cases and 0/28 (0%) of controls ( p =0.002) as 
depicted in figure 10. 
Figure 9: Anti TTG positivity in cases and controls 
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Table 8: Celiac serology and duodenal histology in cases and controls 
 CASES 
Crypto. CLD 
(n=60) 
CONTROLS 
HepB/C rel. CLD 
(n=59) 
p value 
IgA-TTG Ab +ve 
40/58 
-ve 
18/58 
+ve 
16/59 
-ve 
43/59 
0.00 
Titres at diagnosis 
(IU/ML) 
70 43 0.03 
 
Duodenal biopsy Cases (n=51) Controls (n=28)  
Marsh 0 19 0 7 12  
Marsh I/II 13 7 3 6  
MARSH III 11 1 0 0 0.006 
                                                                                                                   p value 0.002  
                                                                                                                                                                 
Table 9: Spectrum of Celiac Disease 
 CASES  
Crypto. CLD 
(n=60) 
CONTROLS  
Hep B/C rel. CLD  
(n=59) 
 Cases who underwent 
duodenal biopsy 
(n=51) 
Controls who underwent 
duodenal biopsy 
(n=28) 
Celiac disease 11 0 
Celiac enteropathy 13 3 
Latent Celiac Disease 19 7 
   
Figure 12: TTG Ab titres (mean +/- 2 SD ) vs Marsh grade in cases and controls  
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Anticardiolipin antibodies in cases: None of the cases had positive cardiolipin antibodies 
(IgA, IgG and IgM). The IgA Cardiolipin antibodies were borderline positive in 4 patients. 
Of these 4 patients , 1 had celiac disease, 2 had celiac enteropathy  and 1 had latent celiac 
disease.(table 10) 
  
Table 10: Anticardiolipin antibodies (IgA, IgG and IgA) in cases (n=28) 
Case 
no. 
IgA-TTG Ab 
(1-> positive 
0->negative) 
Duodenal 
biopsy 
(Marsh 
grade) 
IgA (U/ml) IgM(U/ml) IgG(U/ml) 
1 1 1 6.76 ND# ND 
2 1 3 8.89 ND 4.38 
3 1 1 5.10 ND ND 
4 1 1 13.7 ND 3.73 
5 1 3 9.6 ND ND 
6 1 0 9.9 ND ND 
7 1 3 10.09 ND ND 
8 1 1 7.33 ND 5.35 
9 1 3 ND ND ND 
10 1 0 4.89 ND ND 
11 1 3 ND ND ND 
12 1 0 7.98 ND 4.4 
13 1 1 9.4 ND ND 
14 1 0 11.5 ND 4.17 
15 1 1 10.98 6.61 ND 
16 1 3 5.7 ND 4.76 
17 1 1 6.8 ND ND 
18 1 3 8.48 ND ND 
19 1 3 ND ND 6.32 
20 1 3 6.35 6.4 ND 
21 1 3 ND ND ND 
22 0 0 4.13 ND ND 
23 0 3 ND ND ND 
24 0 - 5.57 ND ND 
25 0 0 8.24 ND 4.03 
26 0 0 4.4 ND ND 
27 0 0 ND ND ND 
28 0 0 ND ND ND 
 
ND# below detection threshold 
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Anticardiolipin antibodies in controls: IgA anticardiolipin antibodies were borderline positive 
in 4 patients of which 1 had celiac enteropathy, 1 had latent celiac disease, 1 had duodenal 
biopsy showing Marsh grade I changes but a negative serology and the fourth had negative 
serology(duodenal biopsy was not done) (table 11). 
IgA anticardiolipin antibody was positive in 1 patient who had a negative serology and a 
normal biopsy. This same patient also had a positive IgG anticardiolipin antibody. This 
patient had a decompensated chronic liver disease secondary to hepatitis B. 
 
Table 11: Anticardiolipin antibodies (IgA, IgG and IgA) in controls (n=32) 
Case no IgA-TTG Ab 
(1->positive 
0->negative 
Duodenal 
biopsy 
(Marsh 
grade) 
IgA(U/ml) IgM(U/ml) IgG(U/ml) 
1 1 0 4.3 ND# 4.2 
2 1 0 11.2 ND 5.18 
3 1 0 ND ND ND 
4 1  5.5 ND 7.9 
5 0  6.5 ND ND 
6 0  6.6 ND ND 
7 0  5.15 14.6 4.75 
8 0  5.5 ND 5.14 
9 1  7.76 ND 6.67 
10 1 0 7.57 ND 5.06 
11 0  4.65 ND 6.1 
12 1  8.89 ND 6.98 
13 0  5.93 ND 4.05 
14 1 0 8.7 15.7 4.08 
15 0  6.63 ND ND 
16 0  6.54 ND 6.84 
17 1  4.03 5.12 ND 
18 1 0 8.2 ND 5.59 
19 0  ND ND 4.76 
20 0  ND ND ND 
21 0  11.04 ND 5.86 
22 0  7.55 ND ND 
23 0 0 ND ND ND 
24 0 0 18.26 ND 15.3 
25 1 1 10.25 ND 4.94 
26 0 0 7.56 ND ND 
27 0  ND ND ND 
28 0 1 12.59 ND 5.6 
29 0 0 ND ND ND 
30 0  5.32 ND ND 
31 0 1 ND ND 6.59 
32 0 1 ND ND ND 
ND# below detection threshold 
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N0N-CIRRHOTIC INTRAHEPATIC PORTAL HYPERTENSION: 
      Of the 60 cases liver biopsy was done in 20 patients of which 13/20 (65%) had Non-
cirrhotic intrahepatic portal hypertension (NCIPH), 7 had cirrhosis. The mean HVPG was 6 
(SD = 5) mm Hg. 
Spectrum of celiac disease in NCIPH pts. 
        Of these 6 pts had villous atrophy on duodenal biopsy and 5 of 6 also had a positive 
IgA-TTG antibody consistent with the diagnosis of celiac disease. 
 
 
 
CELIAC DISEASE:  
        There were 11 cases (cryptogenic CLD) who had celiac disease (IgA-TTG Ab positive 
and Marsh III changes of villous atrophy on duodenal biopsy). Of these, 8 patients had 
symptomatic celiac disease with symptoms of diarrhea, bloating and flatulence and 3 had 
Figure 13: Spectrum of celiac disease in NCIPH patients(n=13) 
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silent celiac disease (i.e. no intestinal symptoms). One patient also had associated dermatitis 
herpetiformis. 
         The mean age of these patients was 40 years. All except one patient had an adult onset 
celiac disease. (One patient had diarrhea from 7 years of age). 10 patients were from eastern 
India and 1 from southern India (Andhra Pradesh). Of these patients 7 underwent liver 
biopsies and 5 had NCIPH, 2 had cirrhosis. 
Table 12: Baseline gut permeability in cases 
Case no IgA-TTG Ab Ab titres 
(U/ml) 
Duodenal 
biopsy(Marsh 
grade) 
Gut permeability 
(inc >0.072)83 
1 + 28 3 0.4468 
2 + 82 3 0.1158 
3 + 25 3 0.142 
4 + 56 3 0.0244 
5 + 49 3 0.0388 
6 + >300 3 0.50024 
7 + 39 3 0.0695 
8 _  3 0.0133 
9 + 40 1 0.0154 
10 + 21 1 0.0122 
11 + 126 1 0.0238 
12 +  1 0.014 
13 _  1 0.009143 
14 _ 1 0.0487 
15 + 51 0 0.625 
16 + 31 0 0.0215 
17 + 0 0.0074 
18 +  0 0.0314 
19 + 82 0 0.0044 
20 + 33 0 0.0071 
21 _  0 0.1703 
22 _  0 0.0408 
23 _ 0 0.01296 
 
Gut permeability using lactulose-mannitol was done in 23 cases (17 pts TTG Ab positive and 
6 TTG Ab negative). Gut permeability was increased in 6 pts, of which 4 had celiac disease 
(villous atrophy on duodenal histology and a positive TTG antibody), 1 had normal biopsy 
and a positive serology and 1 had both negative serology and normal histology (table 12). 
FOLLOW UP:The patients who had celiac disease were advised a gluten-free diet and were 
re-evaluated after a minimum of 3 months. The duration of follow-up was 8 (3 – 14) months, 
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median (range). The compliance was assessed on follow up. All patients except 2 were 
compliant with diet. 
Parameters of patients with celiac disease at baseline and follow-up on Gluten free diet  
Table 13: Parameters at baseline and follow up 
Case 
no 
Months 
of F-up 
Compliance 
score 
Symptom score IgA-TTG 
Ab (titres U/ml) 
Duodenal histology 
(Marsh grade) 
   Baseline F-up Baseline F-up Baseline F-up 
1 6 0 1 0 21 Neg IIIa I 
2#* 8 3 0 0 24 44 IIIa IIIa 
3 9 0 2 1 82 Neg IIIa II 
4 14 0 2 0 25 Neg IIIa I 
5# 5 2 1 1 49 62 IIIa - 
6* 6 0 0 0 >300 >300 IIIb IIIa 
7* 10 0 0 1 39 Neg III I 
8 3 0 1 0 49 Neg III III 
* silent celiac disease 
# non-compliant with gluten free diet 
 
Table 14: Parameters at baseline and follow up of patients with Celiac enteropathy/Latent disease on Gluten free 
diet 
Case 
no 
Months 
of f-up 
Compliance 
score 
Symptom score IgA-TTG 
Ab (titres) 
Duodenal histology 
(Marsh grade) 
   Baseline F-up Baseline f-up Baseline f-up 
1 10 0 2 1 21 Neg I I
2# 11 3 1 1 31 27 0 - 
3 12 0 0 0 26 23 I I 
4 8 0 0 0 50 72 I 0
5 6 0 0 0 33 Neg 0 - 
# non-compliant with gluten free diet 
 
Table 15: Lab parameters at baseline and follow up on GFD in patients with celiac disease 
Case 
no 
Hemoglobin 
(gm/dl) 
Bilirubin 
(mg/dl) 
Albumin 
(gm/dl) 
Prothrombin 
time 
Alanine amino-
transferases(U/L) 
 Baseline F-up Baseline F-up Baseline F-up Baseline F-up Baseline F-up 
1 9.9 8.5 2.5 2.8 3.3 2.5 17.8 17.5 18 18 
2# 12.9 13 1.1 0.9 4.2 4.3 12 13.6 26 14 
3 13.8 13.3 1.1 1.4 4.6 4.4 12.1 10.4 92 50 
4 10.6 11.6 1.4 0.4 4.5 4.4 14.1 13.6 35 22 
5# 12.6 11.7 1 1.8 4.1 3.6 13.7 16 25 26 
6 12 12.1 0.5 1 3.7 3.8 13.3 12.5 59 36 
7 10.3 11.6 1.4 1.4 3.7 3.5 14.5 16 52 56 
8 5.8 15 0.9 1 4.4 4.5 13 13 28 50 
  # non compliant with gluten free diet 
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Table 16: Lab parameters at baseline and f-up on GFD in patients with celiac enteropathy/latent ds. 
Case 
no 
Hemoglobin 
(gm/dl) 
Bilirubin 
(mg/dl) 
Albumin 
(gm/dl) 
Prothrombin 
time(sec) 
Alanine amino-
transferases(U/L) 
 Baseline F-up Baseline F-up Baseline F-up Baseline F-up Baseline F-up 
1 8.4 10.1 0.9 1.1 3.6 4 14.5 13.4 54 44 
2# 6.6 13 2.2 1.1 3.7 4.3 12.4 11 46 63 
3 12.6 12.3 2.4 1.5 4.2 4.3 12.3 11.4 30 22 
4 12.9 10.2 0.6 2 3 2.7 14.9 15.5 42       24 
5 12.6 12.8 1 1.1 3.9 3.6 14.8 14.3 25       35 
# non-compliant with gluten free diet 
 
Table 17: Serial TTG antibody titres in pts who had more than 1 follow up on gluten free diet 
Cases Duodenal histology 
(Marsh grade) baseline  
Titres at 
baseline 
0-3mnths 3-9mnths >9mnths 
1 III 21 - Neg Neg 
2 III* >300 >300 >300  
3 I 25 Neg - Neg 
4 I 31 31  27 
5 I 50 >300  72 
6 0 26 24 - 23 
* silent celiac disease (duodenal histology done on subsequent visits at 3 and 8 mths was consistent 
with villous atrophy despite strict compliance with gluten free diet) 
 
EFFECT OF GFD ON VARIOUS PARAMETERS IN 8 PTS OF CELIAC 
DISEASE WHO CAME FOR FOLLOW UP 
 
 
Figure 14: Effect of GFD on GI symptoms
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On liver functions: 7 of 8 patients had no hepatic decompensation while on gluten-free diet 
on follow up. 1 of 8 patients came with worsening ascites and pedal edema despite strict 
compliance with gluten free diet (fig 15). 
 
 
On transaminases: The transaminases remained the same or improved in the patients with 
celiac disease (figure 16). 
 
 
Figure 15: Effect of GFD on liver function
Figure 16: Effect of GFD on transaminases
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On IgA-TTG antibody titres: 
 
 
        The titres of TTG antibody became negative in 5 of 8 patients who came for follow up 
on a gluten-free diet. The titres showed mild increase in 2 patients who were non-compliant 
with the diet. Another patient who had a silent celiac disease and titres >300 times, remained 
the same despite 8 months of a strict gluten-free diet. 
 
Duodenal histology: 
         Duodenal biopsies were done in 7 of 8 pts on follow up. Of these, 3 patients had 
reversion of villous atrophy to only features of chronic duodenitis (Marsh I). However in 
none of the patients the biopsy returned to normal. In 1 patient there was reversion of crypt 
hyperplasia with preservation of crypt architecture and decrease from moderate villous 
atrophy to normal and mildly atrophic villi. In another patient, the villous atrophy regressed 
from subtotal to moderate atrophy of villi. Of the remaining 2 patients, the histology 
remained the same and despite a strict adherence with gluten free diet. However, in one 
patient who also had dermatitis herpetiformis, the skin lesions disappeared  after 3 months of 
gluten-free diet (fig 18). 
Figure 17: Effect of GFD on Anti TTG Ab titre
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Gut permeability using lactulose mannitol test showed reversal in 1 patient after 6 months of 
gluten free diet. 
 
                      
 
 
 
 
 
 
Figure 18: Effect of GFD on duodenal histology 
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                                     DISCUSSION  
The present study is a prospective case-control study to look at association between celiac 
disease and cryptogenic chronic liver disease (including idiopathic non-cirrhotic intrahepatic 
portal hypertension).  
        We observed celiac disease to be significantly more common in the cases (cryptogenic 
chronic liver disease including idiopathic non-cirrhotic intrahepatic portal hypertension) as 
compared to the controls (pts with Hep B/C related CLD). 
        When these patients were followed on a gluten-free diet for 8 months (3-14) median 
(range) an improvement in the celiac serology was noted with a decrease in titres of IgA-TTG 
antibody from baseline. 
         However, repeat histology showed improvement in only 4 patients with a complete 
reversion of villous atrophy in 3 patients. The histology did not revert to normal in any 
patient. Further no patient showed worsening in histology. The liver functions remained 
stable over follow up. 
        Of the 11 patients of celiac disease, 6 underwent liver biopsies of which 5 (83%) had 
non-cirrhotic intrahepatic portal hypertension.  
        The prevalence of celiac disease was much higher, 11/51 ~ 22% as compared to the 
reported prevalence in India (0.3-1%).66,67 
         Idiopathic non-cirrhotic intrahepatic portal hypertension has been a predominant cause 
of cryptogenic chronic liver disease in our population.2 In the present study of the 60 patients 
with cryptogenic chronic liver disease, liver biopsies were done in 20 patients and 13 (65%) 
had evidence of non-cirrhotic intrahepatic portal hypertension and cirrhosis in 7 patients. In 
another retrospective analysis of the liver biopsies done from june 2005- june 2007 at our 
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centre, of 517 patients who underwent liver biopsies, 62 patients had no documented cause of 
liver disease of which idiopathic non-cirrhotic intrahepatic portal (NCIPH) was identified in 
30 patients ( 48%). 
        In this study we found that celiac serology using IgA-TTG antibody was significantly 
more common in cases (69%) as compared to controls (27%) (p =0.00). 
        The mean titres were also significantly higher in cases 70 IU/L (SD= 60) as against 
controls i.e. 43 (SD=21) (p =0.036). 
        Further once these patients were subjected to duodenal biopsies for histological 
confirmation of the diagnosis of celiac disease we found 12/51 (24%) patients with 
cryptogenic chronic liver disease as against 0/ 28 (0%) had features of villous atrophy or 
Marsh III changes. This prevalence is much higher (approx. 24 fold) than prevalence of celiac 
disease which has already been reported in India66,67. 
       Further evaluation revealed that 19 of 51 patients who underwent duodenal biopsies in 
cases and 8 of 28 patients in the control group had only evidence of intraepithelial 
lymphocytosis with crypt hyperplasia seen in 1 patient in each group. In a study by Kurppa et 
al6 there was a suggestion that mucosal damage develops gradually and patients may 
experience clinical symptoms before histologic changes appear. They studied 70 consecutive 
adults with positive EMA, and of these, 23 had only mild enteropathy (Marsh I–II) and they 
were randomized either to continue on a gluten-containing diet or start GFD. It was noted that 
in the gluten-containing diet group (Marsh I–II) the small-bowel mucosal deterioration was 
seen in all patients, and the symptoms and abnormal antibody titers persisted. In the GFD 
group (Marsh I–II) the symptoms were alleviated, antibody titers decreased, and mucosal 
inflammation diminished equally to celiac controls (Marsh III). In our series also of the 5 
patients who came for follow up after a 9 (6-12) months  mean (range) of gluten free diet 
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TTG antibody titres decreased in 3 patients (in 2 patients became negative ) and histology 
reverted to normal in 1 patient. 
       Adult-onset celiac disease was recognised in 10 cases and in none of the controls. The 
mean age of the patients was 40 years and 9 patients were from the eastern India and 1 patient 
from south India (however there were only 9 patients of south India that were studied to 
begin with). 1 pt of the 11 had symptoms of diarrhea from 7 years of age. In all these patients 
a diagnosis of celiac disease was made after the diagnosis of liver disease. 
       Of these 11 patients the main presentation as diarrhea disturbing life was seen in 4 
patients, 4 patients had minimal diarrhea, bloating and flatulence and 3 had silent celiac 
disease. In another retrospective evaluation of celiac disease and NCIPH by Eapen et al in 
Birmingham 5 patients were diagnosed with celiac disease of which 2 /5 had a silent disease. 
All these 11 patients had come to the hepatology unit for the evaluation of the liver disease 
and were incidentally detected with celiac disease after complete evaluation. 
       Austin et al hypothesized that in patients with celiac disease there occurs enterocyte 
apoptosis which causes production of anti-cardiolipin antibodies which further cause 
obliteration of the small intrahepatic portal venous system causing non-cirrhotic intrahepatic 
portal hypertension. Similarly celiac disease was seen to be associated with non-cirrhotic 
intrahepatic portal hypertension in another retrospective analysis which looked at gut derived 
prothrombotic factors and association with high titre IgA-anticardiolipin antibodies was 
reported. 
       However, in our series of the 28 cases who were checked for the presence of anti-
cardiolipin antibodies (IgA, IgG and IgM) none had raised levels of either of these 
antibodies(i.e titres more than 15 U/ml). The IgA anti-Cardiolipin antibodies were borderline 
positive (titres between 10-15 U/ml) in 4 patients. Of these 4 patients, 1 had celiac disease, 2 
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had celiac enteropathy and 1 had latent celiac disease. In the control group of the 32 patients 
who were checked for the presence of anti-cardiolipin antibodies (IgA, IgG and IgM), IgA 
anticardiolipin antibodies were borderline positive in 4 patients of which 1 had celiac 
enteropathy, 1 had latent celiac disease, 1 had duodenal biopsy showing Marsh I changes but 
a negative serology and the fourth had negative serology (duodenal biopsy was not 
done).(table 10,11) 
       IgA anticardiolpin antibody was positive(titres more than 15U/ml) in only 1 patient who 
had a negative serology and a normal biopsy. This same patient also had a positive IgG 
anticardiolipin antibody. This patient had a decompensated chronic liver disease secondary to 
hepatitis B. 
       This indicates that the pathogenetic mechanisms in our patients with this entity are 
different as compared to the west and require further research. 
       All cases with a positive antibody irrespective of the duodenal histology were subjected 
to a gluten free diet. 
       Of the 11 patients with a positive TTG antibody and villous atrophy on duodenal biopsy 
(Marsh III), 8 came for follow up after a median 8 months, range (3-14 months). 
      Of these 2 patients were non-compliant with the diet who had a corresponding increase in 
titres at follow up. All the remaining 6 who were compliant with the diet had a decline in 
titres with the antibody becoming negative at follow up. This is consistent with the fact the 
titres of antibodies decrease in patients with celiac disease on a gluten free diet and can be 
used for monitoring of compliance with diet. A repeat histology to document response is 
presently not indicated in these patients as histological changes may take longer time to 
improve.7 
54 
 
       The liver functions remained stable on follow up without any new decompensation noted 
in any of the patients, apart from worsening ascites in 1 patient. Most of these patients were 
with CTP score A and hence any definite improvement in liver functions could not be 
determined and also because of a short follow up in our study. 
       On follow up one patient who was diagnosed with celiac disease developed 
hepatocellular carcinoma and underwent radiofrequency ablation for the same. There have 
been only case reports on association of hepatocellular carcinoma with celiac disease.72,73 
       Another patient who was diagnosed as a case of non-cirrhotic intrahepatic portal 
hypertension and silent celiac disease had very high titre TTG antibody (>300 U/ml) 
repeatedly at baseline, at 3 months and 8 months of strict gluten free diet and histology 
showing persistent villous atrophy reflecting possibility of a refractory celiac disease or an 
inadvertent ingestion of gluten84. 
       It is already known that patients with celiac disease have an increased gut permeability 
which causes gut derived toxins , antigens and cytokines to reach the liver via the portal 
circulation and cause liver damage.73,74,75,76 In our series we found increased gut permeability 
in 4 of the 8 (50%) cases of celiac disease who were checked. In 1 patient the gut 
permeability reversed and normalized on follow up on gluten free diet. 
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                                           CONCLUSIONS                                             
       Celiac disease was seen in 22% (11/51) of patients with cryptogenic chronic liver 
disease including idiopathic non-cirrhotic intrahepatic portal hypertension. This is much 
higher than the reported prevalence of celiac disease in India of ~1% (Makharia et al). 
      Of the 11 patients of celiac disease, 5 of 7 patients (71%) who underwent liver biopsy had 
non-cirrhotic intrahepatic portal hypertension. 
       Non-cirrhotic intrahepatic portal hypertension was recognised as the  predominant cause 
of cryptogenic intrahepatic portal hypertension in our unit. Of the 20 cases (Cryptogenic 
CLD) who underwent liver biopsy 65% (13) had NCIPH. 
      Of the 11 patients of celiac disease, 8 came for follow up at 8 (3-14) months median 
(range). 
Adult onset celiac disease was diagnosed in 10 patients. 
        In all patients, celiac disease was recognised after the diagnosis of the liver disease and 3 
patients had silent celiac disease.  
        Reversion of villous atrophy was seen in 3 patients on follow up and serology became 
negative in 5 patients. 
       GI symptoms improved in all patients however an improvement in liver functions could 
not be determined probably because of the short follow up. 
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       Dermatitis herpetiformis was a presentation in 1 patient which resolved with gluten-free 
diet. Refractory celiac disease was suspected in 1 patient with silent disease. Another patient 
was diagnosed with hepatocellular carcinoma on follow up. 
       Increased gut permeability was seen in 6 patients of which 4 had celiac disease and one 
had latent celiac disease. The permeability reversed in one patient on follow up after 6 
months of gluten free diet. 
       In our series of  patients none of the patients of celiac disease had high titres of IgA-
anticardiolipin antibodies (apart from 1 patient with celiac disease who had borderline high 
levels) as against the data from the western population indicating need of further research to 
look at the underlying pathogenetic mechanisms in our population. 
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PROFORMA 
 
NAME: 
HOSPITAL NO: 
AGE: 
SEX: 
ADDRESS: 
 
TEL NO: 
 
MODIFIED KUPPUSWAMY SCORE  
 
CLD: ETIOLOGY 
 
ALCOHOL AUTOIMMUNE VIRUS NAFLD Wilson 
Qty. Dur. ANA Liver 
profile 
HBV HCV DM HTN Lipids BMI  
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CRYPTOGENIC/NCIPH: 
LIVER BIOPSY: 
HVPG: 
VARICES: 
 
 
Sympto
ms 
Duoden
al 
biopsy 
(Marsh 
gd) 
 
TT
G 
 
EM
A 
SPECTRUM 
Silent Symptomat
ic 
Enteropathy Latent FP 
TTG 
         
 
Date of start of gluten free diet: 
 
Assessment of liver functions: 
Decompensation/liver 
functional status 
At entry point After 3-6 months of GFD 
CTP   
MELD   
Ascites   
Encephalopathy   
Variceal bleed/Grade   
Jaundice   
SBP   
Renal failure   
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CELIAC DISEASE: 
 At entry point After 3-6 months of GFD  
IgA TTG Ab (titres)    
IgA EMA    
Duodenal biopsy (Marsh 
Grade) 
   
Intestinal permeability    
 
Quantitative variables: 
Variable At entry point After 3-6 months of GFD 
Hb   
Platelet   
Iron/TIBC   
Ferritin   
Vit. B12/Folate   
Bilirubin   
PT/INR   
Prot/Alb   
Creatinine   
AC/PC   
Lipids   
D-Xylose   
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OTHER FACTORS: 
HYPERSPLENISM(+/-): 
EHPVO(+/-): 
 
PATIENT INFORMATION SHEET AND CONSENT 
 
Study title: Study of spectrum of celiac disease in patients of chronic liver disease 
                    To see the effect of gluten free diet on the outcome of the liver disease 
 
Information sheet (to be read by or explained to the patient) 
 
Celiac disease is an intestinal disease that is associated with allergy to wheat. It has also been 
shown to affect the liver causing chronic liver disease. 
 This study is being done to find out what is the connection between celiac disease and liver 
disease especially in patients in whom the cause of liver damage is not known despite detail 
workup. She would also like to see that in all such patients how a simple gluten free diet can 
help improving both the intestinal and  liver functions in the course of time by doing certain 
tests. 
The study would involve a duodenal biopsy and a serology for TTG antibody including a 
detail clinical examination. If this is positive the patient would be given a wheat- free diet i.e 
avoidance of wheat and all packed items containing wheat as ingredient and a re-evaluation 
would be done after 3-6 months of the same. 
All other tests are only done for your clinical care. 
The results of the tests done in connection with the study may directly benefit you. They are 
likely to indirectly benefit other patients with the disease. 
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The results of the tests will be kept confidential and there will be no direct link of the test 
report with your hospital records. 
You are free to not participate in this study if you do not wish so. 
 
 
CONSENT 
 
I hereby provide my consent for the above research study and to give the necessary 
information and samples. 
I also provide my consent for the blood sample to be preserved for additional research for a 
period of five years without my further approval, under the condition that the results will be 
kept anonymous and not linked to me. 
 
Name:      Hosp. No:     
Study No: 
 
Date:     Signature: 
 
Witnessed by:      
(Name :    ) 
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Title: Is Celiac disease (CD) associated with Cryptogenic Chronic Liver Disease and Non-
cirrhotic Intra-hepatic Portal Hypertension(NCIPH). 
Department:Department of Gastrointestinal Sciences ,Christian Medical College , Vellore 
Name of the candidate: Dr. Rakhi Maiwall 
Degree and subject :DM Branch IV (Gastroenterology) 
Guide: Dr George Chandy 
Abstract: 
Background and Aims: To study the spectrum of CD  in patients with NCIPH /cryptogenic 
chronic liver disease (CLD) and to see the effects of gluten free diet in these patients.          
Methods : Prospective case-control study  looked at CD  in cryptogenic CLD including 
NCIPH (cases) and hepatitis B/C related CLD (controls). IgA–TTG antibody (using 
recombinant human transglutaminase , ELISA (AESKULISA Celichek ) and anticardiolipin 
antibodies (IgG,IgA and IgM) (ELISA Varelisa kit) with titres at the time of diagnosis and  
duodenal biopsy with grading according to Marsh criteria  was done.This was followed by 
subjecting the patients on gluten free diet and reassessing after minimum  of 3 months. To 
study the association, bivariate analyses were done and the associations were studied using 
chi-square test (Fisher exact test). 
Results :60 cases (age 43 (10) years, (mean (SD)), males 46) and 59 controls (age 45 (11) 
years; males 53) were studied. Majority were from eastern India.  
Liver biopsy done in 20 cryptogenic CLD patients showed NCIPH  (13) and cirrhosis (7).  
IgA TTG Ab  was significantly positive in 40/58 cases (69%) with higher mean titres (70 
U/ml) as compared to controls 16/59 (27%) (p = 0.00) mean titres (43 U/ml) (p 0.002). 
  
Marsh III, II/I and 0 were seen in  24%, 39%  and 34%  of cases and 0%, 32% and 68% of 
controls (p=0.002). 
 Of  11 pts.with CD (mean age 43 yrs , 3 with silent disease)  5 of 7 who underwent liver 
biopsy had NCIPH. Follow up on GFD duration median 8 (3 – 14) months , TTG Antibody 
became negative in 5 patients and  villous atrophy reversed in 3 patients.   
IgA anticardiolipin antibodies were not positive in any of the patients with CD. Gut 
permeability was increased in 4 of 8 (50%) pts of CD 
Conclusion: CD was seen in 24% pts. of cryptogenic cld which is much higher than reported 
prevalence in India. Of these 5 of 7 pts (71%) who underwent liver biopsy had NCIPH. 
NCIPH was recognised as the predominant cause of cryptogenic intrahepatic portal 
hypertension in our unit. Adult onset celiac disease was diagnosed in 10 patients.GI 
symptoms improved in all patients however an improvement in liver functions could not be 
determined probably because of the short follow up. 
 
 
 
 
 
 
 
 
 
